1/14
08:42 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/17
09:44 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
12/17
09:44 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
12/17
09:12 am
smmt
Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $18.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) was upgraded by analysts at Barclays PLC from an "underweight" rating to an "equal weight" rating. They now have a $18.00 price target on the stock.
12/17
05:40 am
smmt
Summit Therapeutics upgraded to Equal Weight from Underweight at Barclays
Low
Report
Summit Therapeutics upgraded to Equal Weight from Underweight at Barclays
12/17
05:40 am
smmt
Summit Therapeutics upgraded to Equal Weight from Underweight at Barclays
Low
Report
Summit Therapeutics upgraded to Equal Weight from Underweight at Barclays
11/18
12:00 pm
smmt
Rating for SMMT
Low
Report
Rating for SMMT
11/18
12:00 pm
smmt
Rating for SMMT
Low
Report
Rating for SMMT
11/18
09:00 am
smmt
Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/18
09:00 am
smmt
Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/17
04:21 pm
smmt
Summit Therapeutics initiated with a Peer Perform at Wolfe Research
Low
Report
Summit Therapeutics initiated with a Peer Perform at Wolfe Research
11/17
04:21 pm
smmt
Summit Therapeutics initiated with a Peer Perform at Wolfe Research
Low
Report
Summit Therapeutics initiated with a Peer Perform at Wolfe Research
10/22
09:28 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.
10/22
09:28 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.
Low
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.
10/22
09:13 am
smmt
Rating for SMMT
Low
Report
Rating for SMMT
10/22
09:13 am
smmt
Rating for SMMT
Low
Report
Rating for SMMT
10/21
08:48 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
10/21
08:48 am
smmt
Rating for SMMT
Medium
Report
Rating for SMMT
10/21
08:04 am
smmt
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock, down previously from $50.00.
Medium
Report
Summit Therapeutics (NASDAQ:SMMT) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock, down previously from $50.00.